These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 9867757)
1. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Furuta T; Ohashi K; Kamata T; Takashima M; Kosuge K; Kawasaki T; Hanai H; Kubota T; Ishizaki T; Kaneko E Ann Intern Med; 1998 Dec; 129(12):1027-30. PubMed ID: 9867757 [TBL] [Abstract][Full Text] [Related]
2. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Sugimura H; Ohashi K; Ishizaki T; Kaneko E Clin Pharmacol Ther; 2001 Mar; 69(3):158-68. PubMed ID: 11240980 [TBL] [Abstract][Full Text] [Related]
3. Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient. Furuta T; Takashima M; Shirai N; Xiao F; Hanai H; Ohashi K; Ishizaki T Clin Pharmacol Ther; 2000 Jun; 67(6):684-9. PubMed ID: 10872651 [TBL] [Abstract][Full Text] [Related]
4. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype. Inaba T; Mizuno M; Kawai K; Yokota K; Oguma K; Miyoshi M; Take S; Okada H; Tsuji T J Gastroenterol Hepatol; 2002 Jul; 17(7):748-53. PubMed ID: 12121503 [TBL] [Abstract][Full Text] [Related]
5. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Tanigawara Y; Aoyama N; Kita T; Shirakawa K; Komada F; Kasuga M; Okumura K Clin Pharmacol Ther; 1999 Nov; 66(5):528-34. PubMed ID: 10579481 [TBL] [Abstract][Full Text] [Related]
6. Correlation of CYP2C19 genetic polymorphisms with helicobacter pylori eradication in patients with cirrhosis and peptic ulcer. Lay CS; Lin CJ J Chin Med Assoc; 2010 Apr; 73(4):188-93. PubMed ID: 20457439 [TBL] [Abstract][Full Text] [Related]
7. Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication. Yang JC; Wang HL; Chern HD; Shun CT; Lin BR; Lin CJ; Wang TH Pharmacotherapy; 2011 Mar; 31(3):227-38. PubMed ID: 21361732 [TBL] [Abstract][Full Text] [Related]
8. Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan. Dojo M; Azuma T; Saito T; Ohtani M; Muramatsu A; Kuriyama M Dig Liver Dis; 2001 Nov; 33(8):671-5. PubMed ID: 11785712 [TBL] [Abstract][Full Text] [Related]
9. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Nakagawa K; Sugimura H; Ohashi K; Ishizaki T Pharmacogenetics; 2001 Jun; 11(4):341-8. PubMed ID: 11434512 [TBL] [Abstract][Full Text] [Related]
10. The clinical role of cytochrome p450 genotypes in Helicobacter pylori management. Sapone A; Vaira D; Trespidi S; Perna F; Gatta L; Tampieri A; Ricci C; Cantelli-Forti G; Miglioli M; Biagi GL; Paolini M Am J Gastroenterol; 2003 May; 98(5):1010-5. PubMed ID: 12809821 [TBL] [Abstract][Full Text] [Related]
11. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection. Take S; Mizuno M; Ishiki K; Nagahara Y; Yoshida T; Inaba T; Yamamoto K; Okada H; Yokota K; Oguma K; Shiratori Y Am J Gastroenterol; 2003 Nov; 98(11):2403-8. PubMed ID: 14638340 [TBL] [Abstract][Full Text] [Related]
12. Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers. Aoyama N; Tanigawara Y; Kita T; Sakai T; Shirakawa K; Shirasaka D; Kodama F; Okumura K; Kasuga M J Gastroenterol; 1999; 34 Suppl 11():80-3. PubMed ID: 10616772 [TBL] [Abstract][Full Text] [Related]
13. CYP2C19 genotype and phenotype determined with omeprazole in patients with acid-related disorders with and without Helicobacter pylori infection. Sagar M; Seensalu R; Tybring G; Dahl ML; Bertilsson L Scand J Gastroenterol; 1998 Oct; 33(10):1034-8. PubMed ID: 9829356 [TBL] [Abstract][Full Text] [Related]
14. A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism. Miyoshi M; Mizuno M; Ishiki K; Nagahara Y; Maga T; Torigoe T; Nasu J; Okada H; Yokota K; Oguma K; Tsuji T J Gastroenterol Hepatol; 2001 Jul; 16(7):723-8. PubMed ID: 11446878 [TBL] [Abstract][Full Text] [Related]
15. Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. Sheu BS; Kao AW; Cheng HC; Hunag SF; Chen TW; Lu CC; Wu JJ Aliment Pharmacol Ther; 2005 Feb; 21(3):283-8. PubMed ID: 15691303 [TBL] [Abstract][Full Text] [Related]
16. Clarithromycin resistance, but not CYP2C-19 polymorphism, has a major impact on treatment success in 7-day treatment regimen for cure of H. pylori infection: a multiple logistic regression analysis. Miwa H; Misawa H; Yamada T; Nagahara A; Ohtaka K; Sato N Dig Dis Sci; 2001 Nov; 46(11):2445-50. PubMed ID: 11713950 [TBL] [Abstract][Full Text] [Related]
17. High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Furuta T; Shirai N; Xiao F; Takashita M; Sugimoto M; Kajimura M; Ohashi K; Ishizaki T Hepatogastroenterology; 2003; 50(54):2274-8. PubMed ID: 14696516 [TBL] [Abstract][Full Text] [Related]
18. [Progress of tailor-made treatment of peptic ulcer]. Aoyama N; Shirasaka D; Okumura K Nihon Rinsho; 2002 Jan; 60(1):174-81. PubMed ID: 11808330 [TBL] [Abstract][Full Text] [Related]
19. [Effect of CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with rabeprazole-based triple therapy in Chinese]. He XX; Zhao YH; Hao YT Zhonghua Nei Ke Za Zhi; 2004 Jan; 43(1):13-5. PubMed ID: 14990013 [TBL] [Abstract][Full Text] [Related]
20. Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. Kurzawski M; Gawrońska-Szklarz B; Wrześniewska J; Siuda A; Starzyńska T; Droździk M Eur J Clin Pharmacol; 2006 Oct; 62(10):877-80. PubMed ID: 16912869 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]